Literature DB >> 15098191

[Clinical heterogeneity of Alzheimer's disease. Different clinical profiles can predict the progression rate].

C A Mangone1.   

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a degenerative dementia that may disclose different cognitive, behavioral, psychiatric and functional symptoms since onset. These distinct cognitive profiles support the conception of clinical heterogeneity and account for AD's highly variable rate of progression. In spite of strict diagnostic criteria NINCS ADRDA's and DSM IV the clinical certainty is only about 85%. Mayeux define 4 subtypes: a). Benign: mild cognitive and functional impairment without focal signs and late onset behavioral signs, slow progression; b). Myoclonic: usually of presenile onset with severe cognitive deterioration, mutism and early onset myoclonus; c). Extrapyramidal: early onset akineto rigid signs with severe cognitive, behavioral and psychiatric involvement; d). Typical: gradual and progressive cognitive, behavioral and functional impairment. The differentiation of these subtypes will allow us to define discrete patterns of progression, to define prognostic subgroups, and to homogenize them for clinical research and drug trials. DEVELOPMENT: We examined 1000 charts of probable AD patients from the Santojanni Center. We found 42% extrapyramidal, 35% typical, 15% benign and 8% myoclonic. The early onset of parkinsonism and myoclonus predict a rapidly evolving cognitive impairment and a more severe rate of progression with psychiatric disorders and dependency in activities of daily living. (DADL) Patients with low level of education, low cognitive performance at entry as well as those with rapid rate of cognitive deterioration had a faster rate of progression to DADL.
CONCLUSION: Delusions, low level of education, extrapyramidal signs and motor hyperactivity but not hallucinations, and anosognosia were the best non cognitive predictors of DADL.

Entities:  

Mesh:

Year:  2004        PMID: 15098191

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  5 in total

1.  Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates.

Authors:  Giuseppe Tosto; Sarah E Monsell; Stephen E Hawes; Giuseppe Bruno; Richard Mayeux
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

3.  Memantine-induced Myoclonus in a Patient with Alzheimer Disease.

Authors:  Aditya A Murgai; Mark S LeDoux
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-08-14

4.  Cognitive decline in patients with Alzheimer's disease and its related factors in a memory clinic setting, Shanghai, China.

Authors:  Qianhua Zhao; Bin Zhou; Ding Ding; Satoshi Teramukai; Qihao Guo; Masanori Fukushima; Zhen Hong
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

5.  The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.

Authors:  Federica Barocco; Marco Spallazzi; Letizia Concari; Simona Gardini; Annalisa Pelosi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.